Teva Pharmaceuticals to make 1,000 of its employees redundant following its acquisition of US-based Cephalon last month.

The cuts represent approximately 27% of Cephalon’s entire workforce.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has expected to gather at least $500m in synergies as a result of the acquisition.

The layoffs will not affect Teva’s operations in its home nation Israel, but instead in the US and Europe.

Teva CEO Shlomo Yanai is currently in the US overseeing the merger of Cephalon’s interests.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.